LU88018A1 - Vaccin pour variol virale recombinante de virus de l'herpes - Google Patents
Vaccin pour variol virale recombinante de virus de l'herpes Download PDFInfo
- Publication number
- LU88018A1 LU88018A1 LU88018A LU88018A LU88018A1 LU 88018 A1 LU88018 A1 LU 88018A1 LU 88018 A LU88018 A LU 88018A LU 88018 A LU88018 A LU 88018A LU 88018 A1 LU88018 A1 LU 88018A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- host
- virus
- gene
- vaccinia
- recombinant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 48
- 230000003612 virological effect Effects 0.000 title description 10
- 241001529453 unidentified herpesvirus Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims description 266
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 198
- 239000013612 plasmid Substances 0.000 claims description 198
- 208000007089 vaccinia Diseases 0.000 claims description 198
- 241000700605 Viruses Species 0.000 claims description 157
- 210000004027 cell Anatomy 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 41
- 210000005260 human cell Anatomy 0.000 claims description 39
- 230000010076 replication Effects 0.000 claims description 38
- 108700026244 Open Reading Frames Proteins 0.000 claims description 33
- 108090000288 Glycoproteins Proteins 0.000 claims description 21
- 206010037742 Rabies Diseases 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 238000010367 cloning Methods 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 208000009305 pseudorabies Diseases 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 103
- 241000700618 Vaccinia virus Species 0.000 description 98
- 101100287463 Vaccinia virus (strain Copenhagen) HR gene Proteins 0.000 description 96
- 101100287464 Vaccinia virus (strain Western Reserve) VACWR032 gene Proteins 0.000 description 96
- 108020004414 DNA Proteins 0.000 description 95
- 101100234922 Swinepox virus (strain Kasza) LAP gene Proteins 0.000 description 68
- 101100382200 Vaccinia virus (strain Ankara) MVA018L gene Proteins 0.000 description 68
- 101100382201 Vaccinia virus (strain Copenhagen) C7L gene Proteins 0.000 description 68
- 101100382202 Vaccinia virus (strain Western Reserve) VACWR021 gene Proteins 0.000 description 68
- 230000001629 suppression Effects 0.000 description 59
- 230000006798 recombination Effects 0.000 description 51
- 238000005215 recombination Methods 0.000 description 48
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 37
- 201000003740 cowpox Diseases 0.000 description 34
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 238000012217 deletion Methods 0.000 description 31
- 230000037430 deletion Effects 0.000 description 31
- 238000011144 upstream manufacturing Methods 0.000 description 31
- 101100347634 Acanthamoeba castellanii MIB gene Proteins 0.000 description 30
- 101100523536 Gallus gallus RAF1 gene Proteins 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 239000013598 vector Substances 0.000 description 29
- 108020004705 Codon Proteins 0.000 description 27
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 23
- 230000035897 transcription Effects 0.000 description 22
- 238000013518 transcription Methods 0.000 description 22
- 102000006601 Thymidine Kinase Human genes 0.000 description 21
- 108020004440 Thymidine kinase Proteins 0.000 description 21
- 230000012010 growth Effects 0.000 description 21
- 208000015181 infectious disease Diseases 0.000 description 21
- 238000003780 insertion Methods 0.000 description 21
- 230000037431 insertion Effects 0.000 description 21
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 20
- 210000003501 vero cell Anatomy 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 238000013519 translation Methods 0.000 description 19
- 101150044735 C7L gene Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 241000132028 Bellis Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000029087 digestion Effects 0.000 description 13
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 12
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 12
- 108091081024 Start codon Proteins 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 239000011543 agarose gel Substances 0.000 description 10
- 101150066555 lacZ gene Proteins 0.000 description 10
- 230000037452 priming Effects 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 102000004594 DNA Polymerase I Human genes 0.000 description 9
- 108010017826 DNA Polymerase I Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 101150061732 M2L gene Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 101150096037 N2L gene Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 235000021186 dishes Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 101150116298 D12L gene Proteins 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 101100403768 Vaccinia virus (strain Western Reserve) VACWR029 gene Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 101150039990 B13R gene Proteins 0.000 description 5
- 241000700626 Cowpox virus Species 0.000 description 5
- 102000002464 Galactosidases Human genes 0.000 description 5
- 108010093031 Galactosidases Proteins 0.000 description 5
- 101150071286 SPI-2 gene Proteins 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000007505 plaque formation Effects 0.000 description 5
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 4
- 101150068622 ATI gene Proteins 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101100296652 Caenorhabditis elegans pcp-5 gene Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 4
- 229960000951 mycophenolic acid Drugs 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241001455645 Rabbitpox virus Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000700663 Avipoxvirus Species 0.000 description 2
- 101150095960 B19R gene Proteins 0.000 description 2
- 101150019032 B29R gene Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- PZOHPVWRSNXCRP-QRCCJXOFSA-N GPL-1 Chemical compound C([C@@H](NC(=O)CC(O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCC)C(=O)N[C@H]([C@@H](C)OC1[C@@H]([C@H](O)[C@H](O)[C@H](C)O1)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)C(=O)N[C@H](C)C(=O)N[C@@H](C)COC1[C@@H]([C@H](OC)[C@@H](OC)[C@H](C)O1)O)C1=CC=CC=C1 PZOHPVWRSNXCRP-QRCCJXOFSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101100316834 Vaccinia virus (strain Copenhagen) B20R gene Proteins 0.000 description 2
- 241000700646 Vaccinia virus WR Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 101150046614 C15L gene Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 101150111889 F4 gene Proteins 0.000 description 1
- 101710180399 Glycine-rich protein Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100463789 Mus musculus Pagr1a gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 1
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100028262 U6 snRNA-associated Sm-like protein LSm4 Human genes 0.000 description 1
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 1
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 1
- 101100218420 Vaccinia virus (strain Western Reserve) VACWR204 gene Proteins 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 101900323187 Vaccinia virus Interferon antagonist C7 Proteins 0.000 description 1
- 101900244976 Vaccinia virus Interferon antagonist K1L Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 208000009808 cranioectodermal dysplasia Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 238000001491 hyper Rayleigh scattering spectroscopy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 101150116497 sacm1l gene Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 101150101459 tx gene Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33900489A | 1989-04-17 | 1989-04-17 | |
| US33900489 | 1989-04-17 | ||
| US39448889A | 1989-08-16 | 1989-08-16 | |
| US39448889 | 1989-08-16 | ||
| US07/502,834 US5338683A (en) | 1981-12-24 | 1990-04-04 | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US50283490 | 1990-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU88018A1 true LU88018A1 (fr) | 1992-03-11 |
Family
ID=27407304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU88018A LU88018A1 (fr) | 1989-04-17 | 1991-10-16 | Vaccin pour variol virale recombinante de virus de l'herpes |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US5338683A (de) |
| JP (2) | JP3083839B2 (de) |
| KR (1) | KR920700289A (de) |
| AT (1) | AT405184B (de) |
| AU (1) | AU625623B2 (de) |
| BE (1) | BE1004369A5 (de) |
| CA (1) | CA2014465C (de) |
| CH (1) | CH682671A5 (de) |
| DE (2) | DE4090565C2 (de) |
| DK (1) | DK176464B1 (de) |
| FR (1) | FR2647808B1 (de) |
| GB (1) | GB2246784B (de) |
| IE (1) | IE61098B1 (de) |
| IT (1) | IT1241119B (de) |
| LU (1) | LU88018A1 (de) |
| NL (1) | NL195016C (de) |
| WO (1) | WO1990012882A1 (de) |
Families Citing this family (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| GB9014950D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Ehv-4 glycoprotein vaccine |
| US5674735A (en) * | 1990-07-06 | 1997-10-07 | University Court Of The University Of Glasgow | DNA encoding the EHV-4 gH or gC glycoprotein |
| WO1992005263A1 (en) * | 1990-09-25 | 1992-04-02 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| US7374768B1 (en) * | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| US5759552A (en) * | 1991-03-07 | 1998-06-02 | Virogenetics Corporation | Marek's disease virus recombinant poxvirus vaccine |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| EP0561034B1 (de) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
| DK0538496T3 (da) * | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Rekombinant fjerkrækoppevirus med intakt FPV tk-gen |
| US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
| US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
| WO1994019014A1 (en) * | 1993-02-26 | 1994-09-01 | Syntro Corporation | Recombinant fowlpox virus s-fpv-043 and uses thereof |
| US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
| US6010703A (en) * | 1993-07-26 | 2000-01-04 | Board Of Trustees Operating Michigan State University | Recombinant poxvirus vaccine against feline rhinotracheitis |
| EP0752888B1 (de) * | 1994-03-30 | 2007-08-15 | Virogenetics Corporation | NUKLEOTID- UND AMINOSÄURESEQUENZEN gB, gC UND gD DES HERPESVIRUS DES HUNDES UND IHRE VERWENDUNGEN |
| CA2188447C (en) * | 1994-04-29 | 2002-10-22 | Falko-Gunter Falkner | Recombinant poxviruses with foreign polynucleotides in essential regions |
| WO1998000166A1 (en) | 1996-07-03 | 1998-01-08 | Merial, Inc. | Recombinant canine adenovirus (cav) containing exogenous dna |
| US6183752B1 (en) * | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
| EP1997893A1 (de) | 1998-02-24 | 2008-12-03 | Sisters of Providence in Oregon | Zusammensetzungen mit OX-40-Rezeptor-bindenen Mitteln oder diese codierende Nukleinsäure und Verfahren zur Verbesserung der Antigen-spezifischen Immunantwort |
| KR100743894B1 (ko) | 1998-02-27 | 2007-07-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 백신, 면역치료제 및 그의 이용 방법 |
| WO2000049049A1 (en) | 1999-02-19 | 2000-08-24 | Michigan State University | An antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid |
| CN1348332A (zh) | 1999-03-03 | 2002-05-08 | 宾夕法尼亚大学理事会 | 疫苗和基因治疗组合物以及其制备和使用方法 |
| AU779395B2 (en) | 1999-04-30 | 2005-01-20 | Institut De Recherche Cliniques De Montreal (Ircm) | Mutant human CD80 and compositions for and methods of making and using the same |
| US6355246B1 (en) | 1999-06-10 | 2002-03-12 | Board Of Trustees Of Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
| PL210451B1 (pl) * | 1999-06-10 | 2012-01-31 | Merial Sas | Szczepionka DNA przeciwko wirusowi nosówki psów (CDV) |
| US7419668B1 (en) | 1999-09-02 | 2008-09-02 | Board Of Trustees Of Michigan State University | Vaccine to control equine protozoal myeloencephalitis in horses |
| CA2382026A1 (en) | 1999-09-02 | 2001-03-08 | Ruth A. Vrable | Vaccine to control equine protozoal myeloencephalitis in horses |
| ATE385808T1 (de) * | 1999-12-21 | 2008-03-15 | Merial Sas | Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe |
| KR100815888B1 (ko) * | 2000-07-14 | 2008-03-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신 |
| WO2002028165A2 (en) | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| WO2004022729A1 (en) * | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US20020108132A1 (en) * | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US7176300B2 (en) * | 2001-03-30 | 2007-02-13 | Avigenics, Inc. | Avian lysozyme promoter |
| US7541512B2 (en) * | 2001-03-30 | 2009-06-02 | Synageva Biopharma Corp. | Avians containing a lysozyme promoter transgene |
| EP1478751A4 (de) * | 2001-03-30 | 2005-10-19 | Avigenics Inc | Lysozym-promotor in vögeln |
| FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| US7740863B2 (en) * | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
| US20040037848A1 (en) * | 2001-04-06 | 2004-02-26 | Audonnet Jean-Christophe Francis | Recombinant vaccine against West Nile Virus |
| AU2002329176A1 (en) | 2001-05-25 | 2002-12-23 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
| US7550650B2 (en) * | 2001-09-18 | 2009-06-23 | Synageva Biopharma Corp. | Production of a transgenic avian by cytoplasmic injection |
| US20100333219A1 (en) * | 2001-11-30 | 2010-12-30 | Synageva Biopharma Corp. | Methods of protein production using ovomucoid regulatory regions |
| US7294507B2 (en) * | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7335761B2 (en) * | 2001-11-30 | 2008-02-26 | Avigenics, Inc. | Avian gene expression controlling regions |
| US7135562B2 (en) | 2002-03-14 | 2006-11-14 | University Of Cincinnati | Avian iFABP gene expression controlling region |
| US20040241723A1 (en) * | 2002-03-18 | 2004-12-02 | Marquess Foley Leigh Shaw | Systems and methods for improving protein and milk production of dairy herds |
| EP2204180A3 (de) * | 2002-04-19 | 2010-12-22 | Bavarian Nordic A/S | Modifiziertes Vakziniavirus Ankara zur Impfung Neugeborener |
| PL218318B1 (pl) * | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| US20040170646A1 (en) * | 2002-12-13 | 2004-09-02 | Aventis Pasteur, Inc. | Production of ALVAC on avian embryonic stem cells |
| CN1980571A (zh) * | 2003-01-24 | 2007-06-13 | 阿维季尼克斯股份有限公司 | 禽类及禽蛋中表达的外源蛋白质 |
| US7262027B2 (en) * | 2003-03-14 | 2007-08-28 | Medical College Of Ohio | Polypeptide and DNA immunization against Coccidioides spp. infections |
| EP1606419A1 (de) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systeme und methoden zur erhohung der milchproduktion in tieren |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| WO2004112706A2 (en) | 2003-06-13 | 2004-12-29 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
| NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| US20050214316A1 (en) | 2003-11-13 | 2005-09-29 | Brown Thomas P | Methods of characterizing infectious bursal disease virus |
| MXPA06009452A (es) | 2004-02-19 | 2007-03-15 | Univ Alberta | Polimorfismos del promotor de leptin y sus usos. |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| MX2007006252A (es) | 2004-11-24 | 2009-02-13 | Theraptosis Sa | Nuevos peptidos utiles como inhibidores duales de caspasa-2/-6 y sus aplicaciones biologicas. |
| DE602006013117D1 (de) | 2005-04-25 | 2010-05-06 | Merial Ltd | Nipah-virus-impfstoffe |
| ATE496629T1 (de) * | 2005-07-28 | 2011-02-15 | Pfizer Prod Inc | Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95 identisch zur seq id no: 13 ist enthält. |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| WO2007056614A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7745158B2 (en) * | 2005-12-14 | 2010-06-29 | Kimberly-Clark Worldwide, Inc. | Detection of secreted aspartyl proteases from Candida species |
| DK1976871T3 (da) | 2006-01-13 | 2011-12-12 | Univ Pennsylvania | Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf |
| EP1981905B1 (de) | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Chlamydia-impfstoff |
| BRPI0709282B8 (pt) | 2006-03-29 | 2021-05-25 | Merial Ltd | vacina contra estreptococos |
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| KR101999376B1 (ko) | 2006-07-28 | 2019-07-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 및 이의 사용 방법 |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| WO2008091311A1 (en) | 2007-01-26 | 2008-07-31 | Synageva Biopharma Corp | Transgene expression in avians |
| CA2684923C (en) | 2007-05-02 | 2015-01-06 | Merial Limited | Dna plasmids having improved expression and stability |
| TW200907058A (en) | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| US20090246226A1 (en) * | 2008-03-28 | 2009-10-01 | Zeon Corporation | Avian vaccines possessing a positive marker gene |
| CN107083391A (zh) * | 2008-04-04 | 2017-08-22 | 宾夕法尼亚大学托管会 | 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法 |
| AU2009231598B2 (en) | 2008-04-04 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
| WO2009137577A2 (en) | 2008-05-08 | 2009-11-12 | Merial Limited | Leishmania vaccine using sand fly salivary immunogen |
| US8921536B2 (en) | 2008-10-29 | 2014-12-30 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
| KR101609233B1 (ko) | 2008-10-29 | 2016-04-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개량된 ｈｃｖ 백신 및 이를 이용하는 방법 |
| US9050287B2 (en) | 2009-01-23 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
| CA2653478A1 (en) * | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
| US20100192236A1 (en) * | 2009-01-28 | 2010-07-29 | University Of South Carolina | Modulation of Delta Opioid Receptor Expression |
| JP5797636B2 (ja) | 2009-04-03 | 2015-10-21 | メリアル リミテッド | ニューカッスル病ウイルスをベクターとするトリワクチン |
| US20100284977A1 (en) * | 2009-04-28 | 2010-11-11 | University Of South Carolina | Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters |
| EP2424999A1 (de) | 2009-04-30 | 2012-03-07 | Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) | Modifizierte immunisierungsvektoren |
| TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| EP2477659A4 (de) | 2009-09-14 | 2014-01-15 | Univ Pennsylvania | Impfstoffe und immuntherapeutika mit dafür kodierenden il-15-rezeptor-alpha- und/oder nukleinsäuremolekülen sowie verfahren zu ihrer anwendung |
| US9109014B2 (en) | 2009-11-02 | 2015-08-18 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CN102781952B (zh) | 2010-02-08 | 2015-09-02 | 宾夕法尼亚大学托管会 | 编码rantes的核酸分子、包含其的组合物以及其使用方法 |
| US9109007B2 (en) | 2010-08-18 | 2015-08-18 | Purdue Pharma L.P. | MHC-I restricted epitopes containing non-natural amino acid residues |
| BR112013007486B1 (pt) | 2010-08-31 | 2020-01-28 | Merial Ltd | composição, vetor recombinante de ndv e uso da referida composição |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| JP6099573B2 (ja) | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法 |
| US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| AU2012214141B2 (en) | 2011-02-11 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same |
| EP2694678A2 (de) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Verfahren und zusammensetzungen zur vorhersage der resistenz gegenüber einer antikrebsbehandlung |
| AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| EP2701736A1 (de) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Trunkierte hiv-hüllproteine (env), verfahren und zugehörige zusammensetzungen |
| WO2012166493A1 (en) | 2011-06-01 | 2012-12-06 | Merial Limited | Needle-free administration of prrsv vaccines |
| AU2012321315B2 (en) | 2011-07-11 | 2016-04-14 | Inovio Pharmaceuticals, Inc | Cross-protective arenavirus vaccines and their method of use |
| DK2734230T3 (en) | 2011-07-20 | 2019-01-28 | Merial Ltd | RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE |
| LT2741740T (lt) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
| CA3161127A1 (en) | 2011-10-12 | 2013-04-18 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
| CN103889460B (zh) | 2011-10-24 | 2016-06-15 | 宾夕法尼亚大学理事会 | 改进的hcv疫苗及其使用方法 |
| CA2858884A1 (en) | 2011-12-12 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
| MX354986B (es) | 2011-12-12 | 2018-03-28 | Univ Pennsylvania | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| NZ700470A (en) | 2012-03-20 | 2016-04-29 | Merial Inc | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
| AU2013245950B2 (en) | 2012-04-10 | 2016-04-21 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| ES2689878T3 (es) | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
| HK1216006A1 (zh) | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法 |
| CA2898522A1 (en) | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
| JP6817062B2 (ja) | 2013-03-15 | 2021-01-20 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列、およびそれから作成されるワクチン |
| BR112015022367B1 (pt) | 2013-03-15 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Vacina, molécula de ácido nucleico, e, molécula de aminoácido |
| EA201691993A1 (ru) | 2014-04-03 | 2017-02-28 | Бёрингер Ингельхайм Ветмедика, Инк. | Вакцина к вирусу эпидемической диареи свиней |
| WO2016073410A1 (en) | 2014-11-03 | 2016-05-12 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| US9981033B2 (en) | 2015-06-23 | 2018-05-29 | Merial Inc. | PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof |
| DK3344289T3 (da) | 2015-08-31 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Pestivirusvacciner mod medfødt tremor |
| CA2996613A1 (en) | 2015-09-16 | 2017-03-23 | Boehringer Ingelheim Vetmedica, Inc. | Salmonella choleraesuis-salmonella typhimurium vaccines |
| AR109538A1 (es) | 2016-09-20 | 2018-12-19 | Boehringer Ingelheim Vetmedica Gmbh | Vacuna contra la gripe porcina |
| EA201990711A1 (ru) | 2016-09-20 | 2019-09-30 | Бёрингер Ингельхайм Ветмедика Гмбх | Новый ehv сайт инсерции orf70 |
| WO2018054840A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | New promoters |
| BR112019005511A2 (pt) | 2016-09-20 | 2019-10-01 | Boehringer Ingelheim Vetmedica Gmbh | vetores de adenovírus canino |
| CN109803678B (zh) | 2016-11-03 | 2023-08-22 | 勃林格殷格翰动物保健有限公司 | 抗猪细小病毒的疫苗 |
| EA201991041A1 (ru) | 2016-11-03 | 2019-11-29 | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
| EA201991762A1 (ru) | 2017-01-30 | 2020-01-23 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Вакцины против коронавируса свиней |
| CA3068052A1 (en) | 2017-07-12 | 2019-01-17 | Boheringer Ingelheim Animal Health Usa Inc. | Senecavirus a immunogenic compositions and methods thereof |
| MY201967A (en) | 2017-09-23 | 2024-03-27 | Boehringer Ingelheim Pharma | Paramyxoviridae expression system |
| WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
| RU2750689C1 (ru) | 2017-12-13 | 2021-07-01 | Иновио Фармасьютикалз, Инк. | Противораковые вакцины, направленные на muc16, и их применение |
| PL3737397T3 (pl) | 2017-12-13 | 2023-03-27 | Inovio Pharmaceuticals, Inc. | Szczepionki przeciwnowotworowe ukierunkowane do prame i ich zastosowania |
| JP7485600B2 (ja) | 2017-12-13 | 2024-05-16 | イノビオ ファーマシューティカルズ，インコーポレイティド | Ｂｏｒｉｓを標的とするがんワクチンおよびその使用 |
| WO2019118760A1 (en) | 2017-12-13 | 2019-06-20 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting mesothelin and uses thereof |
| RU2711907C2 (ru) * | 2017-12-22 | 2020-01-23 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Рекомбинантный белок, содержащий антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (варианты) |
| AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
| BR112020019268A2 (pt) | 2018-03-19 | 2021-01-05 | Boehringer Ingelheim Vetmedica Gmbh | Novo ehv com ul18 e/ou ul8 inativados |
| EP3768326A1 (de) | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | Ehv-einführungsstelle ul43 |
| WO2019191005A1 (en) | 2018-03-26 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
| WO2020058341A1 (en) | 2018-09-20 | 2020-03-26 | Boehringer Ingelheim Vetmedica Gmbh | Intranasal vector vaccine against porcine epidemic diarrhea |
| KR102879825B1 (ko) | 2018-09-20 | 2025-11-03 | 베링거잉겔하임베트메디카게엠베하 | 변형된 pedv 스파이크 단백질 |
| JP2023513135A (ja) | 2020-02-06 | 2023-03-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 抗ラブドウイルス抗体を検出するのに有用なポリペプチド |
| EP4225361A1 (de) | 2020-10-05 | 2023-08-16 | Boehringer Ingelheim Animal Health USA Inc. | Fusionsprotein mit circoviridae-kapsidprotein und chimäre virusähnliche partikel daraus |
| US20220160866A1 (en) | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
| JP2025511739A (ja) | 2022-04-05 | 2025-04-16 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ロタウイルスに対するワクチン接種のために有用な免疫原性組成物 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1061898A (en) | 1963-03-07 | 1967-03-15 | Philips Electronic Pharma | Method for protecting dogs against canine distemper |
| US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| WO1984002077A1 (en) * | 1982-11-30 | 1984-06-07 | Us Health | Process for producing poxvirus recombinants for expression of foreign genes |
| EP0162738A1 (de) | 1984-04-09 | 1985-11-27 | MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP | Herstellung von Untereinheiten von Pseudorabiesvirus-Vakzinen |
| US5242829A (en) * | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| EP0261940A3 (de) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren |
| EP0284416B1 (de) * | 1987-03-27 | 1995-02-22 | Nippon Zeon Co., Ltd. | Rekombinantes Avipoxvirus |
| EP0297924A3 (de) * | 1987-07-01 | 1990-07-11 | City Of Hope | Rekombinant vaccinia Virus zur Expression von HSV 1 gB |
| DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| WO1990001546A1 (en) * | 1988-08-05 | 1990-02-22 | Applied Biotechnology, Inc. | Equine herpesvirus-1 vaccine |
| IE68404B1 (en) | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
-
1990
- 1990-04-04 US US07/502,834 patent/US5338683A/en not_active Expired - Lifetime
- 1990-04-12 CA CA002014465A patent/CA2014465C/en not_active Expired - Lifetime
- 1990-04-16 DE DE4090565A patent/DE4090565C2/de not_active Expired - Lifetime
- 1990-04-16 CH CH3982/90A patent/CH682671A5/fr not_active IP Right Cessation
- 1990-04-16 DE DE19904090565 patent/DE4090565T/de active Pending
- 1990-04-16 KR KR1019900702630A patent/KR920700289A/ko not_active Withdrawn
- 1990-04-16 AU AU55520/90A patent/AU625623B2/en not_active Expired
- 1990-04-16 JP JP02507078A patent/JP3083839B2/ja not_active Expired - Lifetime
- 1990-04-16 AT AT0902590A patent/AT405184B/de active
- 1990-04-16 NL NL9020677A patent/NL195016C/nl not_active IP Right Cessation
- 1990-04-16 WO PCT/US1990/002094 patent/WO1990012882A1/en not_active Ceased
- 1990-04-17 BE BE9000425A patent/BE1004369A5/fr not_active IP Right Cessation
- 1990-04-17 FR FR9004910A patent/FR2647808B1/fr not_active Expired - Lifetime
- 1990-04-17 IT IT20063A patent/IT1241119B/it active IP Right Grant
- 1990-04-18 IE IE138090A patent/IE61098B1/en not_active IP Right Cessation
-
1991
- 1991-09-27 GB GB9120655A patent/GB2246784B/en not_active Expired - Lifetime
- 1991-10-15 DK DK199101743A patent/DK176464B1/da not_active IP Right Cessation
- 1991-10-16 LU LU88018A patent/LU88018A1/fr unknown
-
1993
- 1993-09-21 US US08/124,668 patent/US5482713A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/476,500 patent/US6183750B1/en not_active Expired - Lifetime
-
1999
- 1999-12-28 JP JP37276499A patent/JP3246735B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2647808A1 (fr) | 1990-12-07 |
| DE4090565T (de) | 1992-05-14 |
| CA2014465A1 (en) | 1990-10-17 |
| NL195016C (nl) | 2003-06-10 |
| JP2000157292A (ja) | 2000-06-13 |
| KR920700289A (ko) | 1992-02-19 |
| DK176464B1 (da) | 2008-03-31 |
| IT9020063A0 (it) | 1990-04-17 |
| JP3083839B2 (ja) | 2000-09-04 |
| JPH04505248A (ja) | 1992-09-17 |
| GB2246784A (en) | 1992-02-12 |
| AU5552090A (en) | 1990-11-16 |
| WO1990012882A1 (en) | 1990-11-01 |
| NL9020677A (nl) | 1992-02-03 |
| IT9020063A1 (it) | 1991-10-17 |
| GB9120655D0 (en) | 1991-11-27 |
| DK174391A (da) | 1991-12-12 |
| BE1004369A5 (fr) | 1992-11-10 |
| GB2246784B (en) | 1993-04-28 |
| FR2647808B1 (fr) | 1995-03-03 |
| US5338683A (en) | 1994-08-16 |
| CA2014465C (en) | 1999-06-15 |
| DE4090565C2 (de) | 2000-03-09 |
| DK174391D0 (da) | 1991-10-15 |
| JP3246735B2 (ja) | 2002-01-15 |
| IT1241119B (it) | 1993-12-29 |
| IE901380L (en) | 1990-10-17 |
| US5482713A (en) | 1996-01-09 |
| AT405184B (de) | 1999-06-25 |
| AU625623B2 (en) | 1992-07-16 |
| US6183750B1 (en) | 2001-02-06 |
| IE61098B1 (en) | 1994-09-21 |
| CH682671A5 (fr) | 1993-10-29 |
| ATA902590A (de) | 1998-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1004212A5 (fr) | Systeme de selection du domaine de replication dans un hote du poxvirus recombinant. | |
| LU88018A1 (fr) | Vaccin pour variol virale recombinante de virus de l'herpes | |
| FR2644177A1 (fr) | Systeme de selection du domaine de replication dans un hote du poxvirus recombinant | |
| US5225336A (en) | Recombinant poxvirus host range selection system | |
| DE3890874C2 (de) | Rekombinante Viren | |
| Kieny et al. | Expression of rabies virus glycoprotein from a recombinant vaccinia virus | |
| US6340462B1 (en) | Recombinant avipox virus | |
| US5174993A (en) | Recombinant avipox virus and immunological use thereof | |
| JP3411307B2 (ja) | 組み換えアビポックスウイルス、該ウイルスを感染させた細胞の培養及び該ウイルスから誘導されるワクチン | |
| EP0162757B1 (de) | Rabies-Vakzine und Verfahren zur Herstellung | |
| CA2089497A1 (en) | Self-assembling replication defective hybrid virus particles | |
| JP3824619B2 (ja) | 麻疹ウイルス組換え体ポックスウイルスワクチン | |
| AU2016278806A1 (en) | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine | |
| US5597570A (en) | Protein recognized by antibodies raised against native P28 of schistosoma mansoni | |
| JPH11511961A (ja) | 組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用 | |
| US20080112969A1 (en) | Recombinant Herpesvirus Useful in Vaccine Production | |
| McCabe et al. | Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein | |
| Van der Ryst et al. | Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes | |
| JPH10512151A (ja) | Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物 | |
| FR2736358A1 (fr) | Virus myxomateux recombinant | |
| DK176165B1 (da) | Rekombinant fjerkræpoxvirus samt anvendelsen af samme | |
| DK175980B1 (da) | Recombinante vacciniavira og anvendelsen af samme | |
| AU1663601A (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof | |
| IE60309B1 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof |